Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$10.58 - $17.9 $230,644 - $390,219
-21,800 Reduced 72.67%
8,200 $89,000
Q4 2023

Feb 14, 2024

SELL
$17.1 - $22.26 $513,000 - $667,800
-30,000 Reduced 50.0%
30,000 $650,000
Q3 2023

Nov 14, 2023

BUY
$16.75 - $48.98 $502,500 - $1.47 Million
30,000 Added 100.0%
60,000 $1.23 Million
Q1 2023

May 15, 2023

BUY
$37.27 - $46.57 $1.12 Million - $1.4 Million
30,000 New
30,000 $1.26 Million
Q1 2022

May 13, 2022

SELL
$30.71 - $45.71 $7.88 Million - $11.7 Million
-256,600 Reduced 99.46%
1,400 $47,000
Q4 2021

Feb 11, 2022

BUY
$37.06 - $47.11 $8.45 Million - $10.7 Million
228,000 Added 760.0%
258,000 $11 Million
Q3 2021

Nov 12, 2021

BUY
$40.26 - $57.37 $100,650 - $143,425
2,500 Added 9.09%
30,000 $1.33 Million
Q2 2021

Aug 16, 2021

SELL
$54.88 - $79.29 $208,544 - $301,302
-3,800 Reduced 12.14%
27,500 $1.56 Million
Q1 2021

May 17, 2021

BUY
$70.65 - $96.76 $2.21 Million - $3.03 Million
31,300 New
31,300 $2.34 Million
Q2 2020

Aug 14, 2020

SELL
$25.95 - $43.15 $519,000 - $863,000
-20,000 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$26.15 - $77.24 $985,855 - $2.91 Million
-37,700 Reduced 65.34%
20,000 $574,000
Q4 2019

Feb 13, 2020

SELL
$60.18 - $154.77 $288,864 - $742,896
-4,800 Reduced 7.68%
57,700 $4.16 Million
Q3 2019

Nov 14, 2019

BUY
$140.29 - $189.96 $4.55 Million - $6.15 Million
32,400 Added 107.64%
62,500 $8.77 Million
Q2 2019

Aug 13, 2019

BUY
$157.85 - $183.09 $1.59 Million - $1.85 Million
10,100 Added 50.5%
30,100 $5.51 Million
Q4 2018

Jan 30, 2019

BUY
$81.94 - $139.71 $1.64 Million - $2.79 Million
20,000 New
20,000 $1.92 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $342M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.